ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study.

Authors: Pooja Prem Advani, Sofia A. D. S. Braga, Adam Brufsky, Karthik Giridhar, Erica L. Mayer, Kelly Elizabeth McCann, Ruth O'Regan, Cristina Saura Manich, Seth Andrew Wander, Georg Friedrich Bischof, Beth Hillary Lowenthal, Judith D. Bebchuk, Lisa DeFazio Eli, Brian Barnett, Joyce O'Shaughnessy, Tufia C. Haddad

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps1125

Source: Full article

---

Abstract

TPS1125